Jean-Charles Soria, SVP and Oncology Therapeutic Area Head at Amgen, shared on LinkedIn:
“Circulating Tumor Cells: Beyond ctDNA in Precision Oncology
CTCs ≠ ctDNA: Beyond mutations, CTCs reveal real-time protein and RNA expression – useful for target discovery and resistance monitoring.
Liquid biopsy advantage: Noninvasive CTC analysis enables dynamic tracking of tumor evolution, therapy response and MRD.
Prognostic power: High CTC counts in early disease predict relapse; in metastatic disease, counts stratify prognosis and guide treatment intensity.
Therapeutic targets: HER2, ER, AR, PSMA, PD-L1, EGFR, ALK—CTCs expose actionable biomarkers and resistance mechanisms in real time.”
More posts featuring Jean-Charles Soria.